1. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
- Author
-
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M, International Cancer of Pancreas Screening (CAPS) Consortium, Arcidiacono P.G., (Milan, Italy), Detlef Bartsch (Marburg, Germany), Katharina Biermann (Rotterdam, The Netherlands), Terri Brentnall (Washington, USA), Amitabh Chak (Ohio, Petr Dite (Brno, Czech Republic), Timothy Donahue (California, Dayna Early (Missouri, James Farrell (California, Carlos Fernandez-Del Castillo (Massachusetts, Harold Frucht (New York, Noriyoshi Fukushima (Tochigi, Japan), Jenny Geurts (Wisconsin, Pascal Hamell (Clichy, France), Julio Iglesias-Garcia (Santiago de Compostela, Spain), Alison Klein (Maryland, Guenter Kloeppel (Munich, Jesse Lachter (Haifa, Israel), Peter Langer (Marburg, Jeffrey Lee (Texas, Michael Levy (Minnesota, Hiroyuki Maguchi (Sapporo, Daniel Margolis (Los Angeles, Takao Ohtsuka (Fukuoka, Sara Olson (New York, NY), Gloria Petersen (Minnesota, Thomas Savides (California, Sapna Syngal (Massachusetts, Eric Tamm (Texas, Masao Tanaka (Fukuoka, Hans Vasen (Leiden, Anja Wagner (Erasmus, Huamin Wang (Texas, David Williams (Sydney, Australia), Kenjii Yamao (Nagoya, Canto, Mi, Harinck, F, Hruban, Rh, Offerhaus, Gj, Poley, Jw, Kamel, I, Nio, Y, Schulick, R, Bassi, C, Kluijt, I, Levy, Mj, Chak, A, Fockens, P, Goggins, M, Bruno, M, International Cancer of Pancreas Screening (CAPS), Consortium, Arcidiacono, P. G., (Milan, Italy), Detlef Bartsch, (Marburg, Germany), Katharina, Biermann (Rotterdam, The, Netherlands), Terri Brentnall, (Washington, USA), Amitabh, Chak (Ohio, Petr Dite, (Brno, Czech, Republic), Timothy Donahue, (California, Dayna Early, (Missouri, James Farrell, (California, Carlos Fernandez-Del Castillo, (Massachusett, Harold Frucht (New, York, Noriyoshi, Fukushima (Tochigi, Japan), Jenny Geurts, (Wisconsin, Pascal Hamell, (Clichy, France), Julio Iglesias-Garcia (Santiago de, Compostela, Spain), Alison Klein, (Maryland, Guenter Kloeppel, (Munich, Jesse Lachter, (Haifa, Israel), Peter, Langer (Marburg, Jeffrey Lee, (Texa, Michael Levy, (Minnesota, Hiroyuki Maguchi, (Sapporo, Daniel Margolis (Los, Angele, Takao Ohtsuka, (Fukuoka, Sara Olson (New, York, NY), Gloria Petersen, (Minnesota, Thomas Savides, (California, Sapna Syngal, (Massachusett, Eric Tamm, (Texa, Masao Tanaka, (Fukuoka, Hans Vasen, (Leiden, The Netherlands), Anja Wagner, (Erasmu, Huamin Wang, (Texa, David Williams, (Sydney, Australia), Kenjii Yamao, (Nagoya, Pathology, Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Gastroenterology and Hepatology, and Gastroenterology & Hepatology
- Subjects
medicine.medical_specialty ,Cholangiopancreatography, Magnetic Resonance ,Colorectal cancer ,Pancreatic Intraepithelial Neoplasia ,Endosonography ,Pancreatectomy ,SDG 3 - Good Health and Well-being ,Risk Factors ,Pancreatic cancer ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Magnetic Resonance ,Early Detection of Cancer ,Intraepithelial neoplasia ,Magnetic resonance cholangiopancreatography ,Endoscopic retrograde cholangiopancreatography ,medicine.diagnostic_test ,Intraductal papillary mucinous neoplasm ,business.industry ,General surgery ,Carcinoma ,Gastroenterology ,Age Factors ,Cancer ,medicine.disease ,Cholangiopancreatography ,Pedigree ,Pancreatic Neoplasms ,Treatment Outcome ,Follow-Up Studies ,Mutation ,Neoplasm Grading ,business - Abstract
Background Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplasia. Objective To develop consortium statements on screening, surveillance and management of high-risk individuals with an inherited predisposition to PC. Methods A 49-expert multidisciplinary international consortium met to discuss pancreatic screening and vote on statements. Consensus was considered reached if ≥75% agreed or disagreed. Results There was excellent agreement that, to be successful, a screening programme should detect and treat T1N0M0 margin-negative PC and high-grade dysplastic precursor lesions (pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm). It was agreed that the following were candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs; patients with Peutz–Jeghers syndrome; and p16, BRCA2 and hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers with ≥1 affected FDR. Consensus was not reached for the age to initiate screening or stop surveillance. It was agreed that initial screening should include endoscopic ultrasonography (EUS) and/or MRI/magnetic resonance cholangiopancreatography not CT or endoscopic retrograde cholangiopancreatography. There was no consensus on the need for EUS fine-needle aspiration to evaluate cysts. There was disagreement on optimal screening modalities and intervals for follow-up imaging. When surgery is recommended it should be performed at a high-volume centre. There was great disagreement as to which screening abnormalities were of sufficient concern to for surgery to be recommended. Conclusions Screening is recommended for high-risk individuals, but more evidence is needed, particularly for how to manage patients with detected lesions. Screening and subsequent management should take place at high-volume centres with multidisciplinary teams, preferably within research protocols.
- Published
- 2013